0001388658-22-000149.txt : 20221101 0001388658-22-000149.hdr.sgml : 20221101 20221101160656 ACCESSION NUMBER: 0001388658-22-000149 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221101 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221101 DATE AS OF CHANGE: 20221101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iRhythm Technologies, Inc. CENTRAL INDEX KEY: 0001388658 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 208149544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37918 FILM NUMBER: 221350255 BUSINESS ADDRESS: STREET 1: 699 8TH STREET STREET 2: SUITE 600 CITY: San Francisco STATE: CA ZIP: 94103 BUSINESS PHONE: 415-632-5700 MAIL ADDRESS: STREET 1: 699 8TH STREET STREET 2: SUITE 600 CITY: San Francisco STATE: CA ZIP: 94103 FORMER COMPANY: FORMER CONFORMED NAME: IRhythm Technologies, Inc. DATE OF NAME CHANGE: 20110429 FORMER COMPANY: FORMER CONFORMED NAME: IRhythm Technologies Inc DATE OF NAME CHANGE: 20070201 8-K 1 irtc-20221101.htm 8-K irtc-20221101
0001388658false00013886582022-11-012022-11-01


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
FORM 8-K 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 1, 2022
iRhythm Technologies, Inc.
(Exact name of Registrant as specified in its charter) 
Delaware001-3791820-8149544
(State or other jurisdiction of
incorporation or organization)		(Commission
File Number)		(I.R.S. Employer
Identification Number)
699 8th Street, Suite 600
San Francisco, California 94103
(Address of principal executive office) (Zip Code)
(415) 632-5700
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, Par Value $0.001 Per ShareIRTCThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 






Item 2.02. Results of Operations and Financial Condition.

On November 1, 2022, iRhythm Technologies, Inc. issued a press release regarding its financial results for the third quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
This information is intended to be furnished under Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
 
Exhibit No. Description
99.1 
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
IRHYTHM TECHNOLOGIES, INC.
Date: November 1, 2022
By:/s/ Quentin S. Blackford
Quentin S. Blackford
Chief Executive Officer


 EX-99.1 2 irtcq32022ex991pressrelease.htm EX-99.1 Document
Exhibit 99.1




iRhythm Technologies Announces Third Quarter 2022 Financial Results

SAN FRANCISCO, November 1, 2022 - iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today reported financial results for the three months ended September 30, 2022.

Third Quarter 2022 Financial Results
•Revenue of $103.9 million, a 21.6% increase compared to third quarter 2021
•Gross margin of 68.3%, a 2.6 percentage point improvement compared to third quarter 2021
•Cash, cash equivalents and short-term investments of $203.5 million as of September 30, 2022
•Updating fiscal year 2022 revenue guidance to a range of approximately $407 million to $411 million
•Improving profitability profile, including updated fiscal year 2022 adjusted EBITDA guidance of negative $10 to negative $12 million

Recent Operational Highlights
•Third quarter registration growth of 22% year-over-year
•Presentations at the European Society of Cardiology (ESC) in August highlighted Zio XT increased arrhythmia detection rates by 216% and reduced time to detection as compared to traditional Holter monitors1
•Detailed refreshed vision and mission, long-term growth strategies, innovation pipeline and financial goals during analyst and investor day in September
•Upcoming data presentations at the American Heart Association (AHA) in Chicago, IL, from November 5-7, 2022

"Despite the ongoing staffing and capacity challenges, we grew registration volumes by more than 20% in the third quarter, achieving our highest daily registration volumes ever as we exited September," said iRhythm CEO and President, Quentin Blackford. "However, within the quarter, we also realized softness in returned devices - which impacted our ability to perform our services and realize revenue which muted our growth. We view this as persisting into the fourth quarter. These dynamics, as well as fourth quarter trends in account staffing and capacity challenges as well as Zio AT utilization, have led to us reducing our full year revenue guidance."

"While disappointing, we continue to be encouraged by the underlying momentum of the business as demonstrated by the accelerating daily registration growth in the third quarter. As we shared during our Investor and Analyst Day in September, we continue to believe iRhythm's innovative device with differentiated AI capabilities and clinically actionable data insights is the gold standard in the space and sets us apart in the marketplace. We remain confident in the strong fundamentals of our business and are dedicated to bringing our innovative solutions to the millions of patients who may benefit," concluded Mr. Blackford.

Third Quarter Financial Results
Revenue for the three months ended September 30, 2022 increased 21.6% to $103.9 million, from $85.4 million during the same period in 2021. The increase was primarily driven by Zio XT and AT volume growth as well as an increase in net average selling price.

Gross profit for the third quarter of 2022 was $70.9 million, up 26.4% from $56.1 million during the same period in 2021, while gross margins were 68.3%, up from 65.7% during the same period in 2021. The increase in gross profit was primarily due to increased volume and average selling price, partially offset by increases in cost per unit.

Adjusted operating expenses for the third quarter of 2022 were $89.7 million, compared to $79.4 million during the same period in 2021. This increase in adjusted operating expenses resulted primarily from increased resources to scale and higher bad debt expense as a result of incremental volumes. Operating expenses for the third quarter of 2022 were $92.0 million, compared to $79.4 million for the same period in 2021.

Adjusted net loss for the third quarter of 2022 was $19.1 million, or a loss of $0.63 per share, compared with an adjusted net loss of $23.7 million, or a loss of $0.81 per share, for the same period in 2021. Net loss for the third quarter of 2022 was $21.5 million, or a loss of $0.71 per share, compared with net loss of $23.7 million, or a loss of $0.81 per share, for the same period in 2021.

Cash, cash equivalents and short-term investments were $203.5 million as of September 30, 2022.




Exhibit 99.1




Updated 2022 Annual Guidance
Given volume trends in the third quarter and anticipated volume contributions in the fourth quarter, iRhythm is updating its fiscal year 2022 revenue guidance to range from approximately $407 to $411 million, which represents approximately 26% to 27% growth over the prior year results. This compares to prior fiscal year 2022 revenue guidance of $415 to $420 million.

Gross margin for the fiscal year 2022 is expected to range from approximately 68% to 69% and adjusted operating expenses are expected to range between approximately $360 and $365 million. Adjusted EBITDA for the full year 2022 is expected to range from negative $10 to negative $12 million. This compares to prior fiscal year 2022 adjusted operating expense guidance of $375 and $385 million and prior fiscal year 2022 adjusted EBITDA guidance of negative $12.5 to negative $17.5 million.

Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event, which will be available on the investors section of the Company’s website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Use of Non-GAAP Financial Measures
We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release, including adjusted EBITDA, adjusted net loss, adjusted net loss per share and adjusted operating expenses. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to this press release for additional information and reconciliations of such non-GAAP financial measures.

Adjusted EBITDA excludes non-cash operating charges for stock-based compensation, depreciation and amortization as well as non-operating items such as interest income, interest expense, impairment and restructuring charges, and transformation costs.

We exclude the following items from non-GAAP financial measures for adjusted net loss, adjusted net loss per share and adjusted operating expenses:

•impairment and restructuring charges, and
•transformation costs to scale the organization.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance, market opportunity, the potential impact of Medicare reimbursement rates for the CPT codes primarily relied upon for the Company’s Zio XT services, ability to penetrate the market, anticipated productivity improvements and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filing made with the Securities and Exchange Commission, including those on the Form 10-Q expected to be filed on or about November 3, 2022. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact:Media Contact:
Stephanie ZhadkevichMorgan Mathis
(919) 452-5430(310) 528-6306
investors@irhythmtech.comirhythm@highwirepr.com

1.Ameenathul M. Fawzy MB, Jade Edmonds, Anthony Shannon, David J. Wright MD. A Service Evaluation of Zio XT: The Liverpool Experience. In: ESC Congress 2022, August 26 - 29, 2022 Barcelona, Spain.

Exhibit 99.1




IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)
September 30,December 31,
20222021
Assets
Current assets:
Cash and cash equivalents$71,222 $127,562 
Short-term investments132,316 111,569 
Accounts receivable, net60,534 46,430 
Inventory14,452 10,268 
Prepaid expenses and other current assets7,326 9,693 
Total current assets285,850 305,522 
Property and equipment, net71,515 55,944 
Operating lease right-of-use assets62,010 84,587 
Goodwill862 862 
Other assets20,153 16,052 
Total assets$440,390 $462,967 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$7,404 $10,509 
Accrued liabilities60,264 51,486 
Deferred revenue3,003 3,049 
Debt, current portion— 11,667 
Operating lease liabilities, current portion12,920 11,142 
Total current liabilities83,591 87,853 
Debt, noncurrent portion34,931 9,690 
Other noncurrent liabilities1,163 697 
Operating lease liabilities, noncurrent portion81,481 85,212 
Total liabilities201,166 183,452 
Stockholders’ equity:
Preferred Stock— — 
Common stock28 27 
Additional paid-in capital741,879 685,594 
Accumulated other comprehensive loss(681)(61)
Accumulated deficit(502,002)(406,045)
Total stockholders’ equity239,224 279,515 
Total liabilities and stockholders’ equity$440,390 $462,967 


Exhibit 99.1




IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share data)

Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Revenue, net$103,875 $85,432 $298,304 $241,021 
Cost of revenue32,954 29,284 95,379 78,737 
Gross profit70,921 56,148 202,925 162,284 
Operating expenses:
Research and development11,448 8,685 33,935 26,801 
Selling, general and administrative80,559 70,745 235,468 203,227 
Impairment and restructuring charges— — 26,608 — 
Total operating expenses92,007 79,430 296,011 230,028 
Loss from operations(21,086)(23,282)(93,086)(67,744)
Interest expense(614)(279)(3,125)(921)
Other income (expense), net365 (76)450 103 
Loss before income taxes(21,335)(23,637)(95,761)(68,562)
Income tax provision116 94 196 308 
Net loss$(21,451)$(23,731)$(95,957)$(68,870)
Net loss per common share, basic and diluted$(0.71)$(0.81)$(3.22)$(2.35)
Weighted-average shares, basic and diluted30,055,166 29,397,845 29,836,601 29,294,559 


Exhibit 99.1




IRHYTHM TECHNOLOGIES, INC.
Reconciliation of GAAP to Non-GAAP Financial Information
(unaudited)
(in thousands, except per share data)
Three Months Ended
September 30,		Nine Months Ended
September 30,
Adjusted EBITDA reconciliation2022202120222021
Net loss$(21,451)$(23,731)$(95,957)$(68,870)
Income tax provision116 94 196 308 
Depreciation and amortization3,436 2,549 9,930 6,738 
Interest expense, net15 223 2,198 717 
Stock-based compensation12,945 12,160 41,946 42,651 
Impairment and restructuring charges— — 26,608 — 
Transformation costs2,315 — 2,748 — 
Adjusted EBITDA$(2,624)$(8,705)$(12,331)$(18,456)

Three Months Ended
September 30,		Nine Months Ended
September 30,
 2022202120222021
Adjusted net loss reconciliation
Net loss, as reported$(21,451)$(23,731)$(95,957)$(68,870)
Impairment and restructuring charges— — 26,608 — 
Transformation costs2,315 — 2,748 — 
Adjusted net loss$(19,136)$(23,731)$(66,601)$(68,870)
Adjusted net loss per share reconciliation
Net loss per share, as reported$(0.71)$(0.81)$(3.22)$(2.35)
Impairment and restructuring charges per share— — 0.89 — 
Transformation costs per share0.08 — 0.09 — 
Adjusted net loss per share$(0.63)$(0.81)$(2.24)$(2.35)
Adjusted operating expense reconciliation
Operating expense, as reported$92,007 $79,430 $296,011 $230,028 
Impairment and restructuring charges— — (26,608)— 
Transformation costs(2,315)— (2,748)— 
Adjusted operating expense$89,692 $79,430 $266,655 $230,028 

 EX-101.SCH 3 irtc-20221101.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 irtc-20221101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 irtc-20221101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information Document
Nov. 01, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 01, 2022
Entity Registrant Name iRhythm Technologies, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37918
Entity Tax Identification Number 20-8149544
Entity Address, Address Line One 699 8th Street
Entity Address, Address Line Two Suite 600
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94103
City Area Code 415
Local Phone Number 632-5700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.001 Per Share
Trading Symbol IRTC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001388658
Amendment Flag false
XML 7 irtc-20221101_htm.xml IDEA: XBRL DOCUMENT 0001388658 2022-11-01 2022-11-01 0001388658 false 8-K 8-K 2022-11-01 iRhythm Technologies, Inc. DE 001-37918 20-8149544 699 8th Street Suite 600 San Francisco CA 94103 415 632-5700 false false false false Common Stock, Par Value $0.001 Per Share IRTC NASDAQ false 2022-11-01 EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://www.irhythmtech.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports irtc-20221101.htm irtc-20221101.xsd irtc-20221101_lab.xml irtc-20221101_pre.xml irtcq32022ex991pressrelease.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "irtc-20221101.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "irtc-20221101.htm" ] }, "labelLink": { "local": [ "irtc-20221101_lab.xml" ] }, "presentationLink": { "local": [ "irtc-20221101_pre.xml" ] }, "schema": { "local": [ "irtc-20221101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "irtc", "nsuri": "http://www.irhythmtech.com/20221101", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "irtc-20221101.htm", "contextRef": "i803aad7a165e45aa80ba4f915e27c09a_D20221101-20221101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Document and Entity Information Document", "role": "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "irtc-20221101.htm", "contextRef": "i803aad7a165e45aa80ba4f915e27c09a_D20221101-20221101", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.irhythmtech.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001388658-22-000149-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001388658-22-000149-xbrl.zip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